Recently, the 2025 “National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalogue” was officially announced. This time, 114 new drugs were added to the national basic medical insurance catalogue, and 29 drugs were added at the same time. Earlier, it was reported that Renhui Biotech's GLP-1 drug benaglutide was transferred out. Regarding the “transferred out” statement, Renhui Biotech told reporters on December 12 that this was the result of voluntarily submitting an application to the National Health Insurance Administration in July 2025 after careful evaluation based on multiple factors such as the company's overall strategic development plan, commercialization layout, and comprehensive cost considerations. Renhui Biotech said it sincerely thanks the National Health Insurance Administration for supporting innovative pharmaceutical companies and hypoglycemic versions of benaglutide. This adjustment is the company's active strategic choice based on the development stage. In the short term, the company hopes to serve patients in urgent need more accurately by focusing on the segment of reproductive preparation and weight loss, creating social benefits while also achieving optimal allocation and sustainable development of the company's resources.

Recently, the 2025 “National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalogue” was officially announced. This time, 114 new drugs were added to the national basic medical insurance catalogue, and 29 drugs were added at the same time. Earlier, it was reported that Renhui Biotech's GLP-1 drug benaglutide was transferred out. Regarding the “transferred out” statement, Renhui Biotech told reporters on December 12 that this was the result of voluntarily submitting an application to the National Health Insurance Administration in July 2025 after careful evaluation based on multiple factors such as the company's overall strategic development plan, commercialization layout, and comprehensive cost considerations. Renhui Biotech said it sincerely thanks the National Health Insurance Administration for supporting innovative pharmaceutical companies and hypoglycemic versions of benaglutide. This adjustment is the company's active strategic choice based on the development stage. In the short term, the company hopes to serve patients in urgent need more accurately by focusing on the segment of reproductive preparation and weight loss, creating social benefits while also achieving optimal allocation and sustainable development of the company's resources.